VTI Announces Launch of InterGraft™ Biologics

The InterGraft™ series features osteoinductive and wound care scaffolds to aid in implantation and overall surgical success. This includes Matrix OI®, demineralized bone matrix in various forms such as strips, blocks, crunch, and putty, each containing all 5 bone-forming elements (chondrocytes, osteocytes, bone marrow cells, cartilage, and new bone) to optimize bone growth and fusion.

“When surgeons are performing spinal procedures and are concerned for their patients’ health, the biologics that are used to aid the healing process are essential to a successful fusion. VTI is proud to supply regenerative osteobiologics to accompany our innovative modular spinal implants. Our concern is with patients’ recovery and increased mobility, and with surgeons’ ability to access the products needed for a successful procedure,” comments Matt Kyle, President & CEO at VTI.

The InterGraft™ biologics are 100% DBM % by weight, have pliable BMP that is a containment scaffold for stem cells, are processed aseptically using the proprietary BioRinse™ sterilization technology, and is in accordance with AATB standards and FDA federal regulations.

About Vertebral Technologies, Inc.

Vertebral Technologies, Inc. (VTI) is a privately held company based in Minnetonka, MN, USA. VTI is dedicated to the design, development, manufacturing and marketing of medical devices to address painful conditions of the spine through less-invasive surgical approaches. Founded in 2005, VTI’s products utilize its unique modular-assembly technology to deliver solutions optimized for both surgeons and their patients. VTI has sold over 7,000 InterFuse modular interbody fusion devices worldwide to-date.

For more information visit, http://www.vti-spine.com or contact Brian Thron at marketing(at)vti-spine(dot)com or +1.877-912-5401

# # #

< Return to All Press Releases